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Oligonucleotides used for cancer therapy are N3' P5' phosphoramidates (DNA analogues).
GRN163L (Imetelstat) (GeronTM corporation): most successful oligonucleotide inhibitor to date.
Advantages of GRN163L for cancer therapy:
• N3' → P5' thiophosphoramidate (NPS) (fig. 4):
• High thermodynamic stability.
• Resistance to cellular nucleases: long half-life.
• High target sequence specificity.
• Low nonspecific affinity towards proteins.
• Lack of RNaseH induction: reduces potential side
effects of binding to unspecific RNAs.
Figure 5: GRN163L mechanism of action: GRN163L acts as a competitive inhibitor of telomerase
by complementary binding to the hTR template. Therefore, GRN163L specifically prevents binding
of the hTR active site (template) to telomere ends, thus blocking telomerase function. Left: telomere
lengthening by telomerase. Right: inhibition of telomerase activity by GRN163L.
• Lipid group attached to 5': lipid soluble, cell permeable,
enhanced cellular uptake. (fig. 4).
• Good bioavaliability and efficient biodistribution to all
major organs in vivo.
• Polyanionic compound: not likely to be a substrate for
common mechanisms of multidrug resistance (important
for targeting cancer stem cells).
3. Oligonucleotides as telomerase inhibitors: GRN163L (Imetelstat®)
Key advantages of telomerase as a target for cancer therapy:
1. Critical for cancer cell survival (fig. 2).
2. Widespread expression in 85% of human cancers (universality).
3. Not expressed in most human somatic cells (specificity).
4. Low expression in stem cells of highly proliferative tissues (low toxicity).
5. Cancer cells possess shorter telomeres than normal cells (wide
therapeutic window).
6. Ability to target cancer stem cells (fig. 3).
Figure 2: Inactivation of telomerase in cancer cells leads to telomere
shortening and crisis, inducing apoptosis. ALT: alternative lengthening of
telomeres through recombination.
Figure 3: Telomerase-based therapies
are able to target cancer stem cells
(CSC). CSC are a rare population of
cells within a tumor that possess self-
renewal capacity and pluripotency.
CSC are responsible of tumor initiation
and maintenance, and often possess
drug resistance mechanisms.
Telomeres are non-coding DNA sequences at the ends
of chromosomes. Traditional DNA polymerases are
unable to replicate the ends of telomeres. This
incomplete replication leads to the loss of telomeric
DNA with each round of cell division. Therefore,
telomeres act as a “mitotic clock”: progressive telomere
shortening limits cellular lifespan (fig. 1).
Telomerase is a ribonucleoprotein (hTR RNA + hTERT
protein) that counteracts progressive telomere
shortening during cellular replication. Telomerase is not
active in most human somatic cells, with the exception
of proliferative stem cells.
Conversely, telomerase is reactivated in more than 85%
of human cancers. The upregulation of telomerase
maintains telomere length and provides cancer cells
with cellular immortality (a hallmark of cancer) (fig. 1).
Figure 1. Telomere shortening in germ cells,
somatic cells and cancer cells. In normal cells,
telomere shortening induces senescence (M1).
However, cells that have acquired an inactivation of
cell cycle checkpoint proteins are able to keep on
dividing (extended lifespan) and continue to lose
telomeric sequences until they reach a crisis stage
(M2), which induces apoptosis.
Cancer cells bypass senescence due to mutations in
the p53/p16/Rb pathways and bypass crisis through
the reactivation of telomerase or ALT pathway. Thus,
cancer cells become immortal.
5. Conclusion and future prospects
What are the main safety concerns regarding telomerase inhibition therapies?
As normal stem cells transiently express telomerase, one major concern associated
with the use of telomerase inhibitors is the potential decline of regenerative capacity
in stem cells (not seen to date).
Will tumor cells evolve escape mechanisms to telomerase based therapies?
Pre-existing or new refractory cancer cells are likely to be found regardless of the
therapeutic approach. Therefore, a significant consideration is the potential for
selecting for the alternative lengthening of telomeres (ALT) pathway.
Which are the drawbacks when using
telomerase inhibitors such as GRN163L?
The phenotypic lag: treatment with telomerase
inhibitors may require many rounds of cell division
until telomeres become critically short and
apoptosis is induced.
Which are the most suitable applications for
telomerase inhibitor drugs like GRN163L?
Using GRN163L in combination with conventional
chemotherapy and radiotherapy treatment should
lead to a more durable response and decreased
disease recurrence (fig. 12).
Figure 4: GRN163L 
chemical structure
Figure 12. Synergistic effects are observed when combining
GRN163L with traditional chemotherapeutic drugs.
4.2 Clinical studies
Table 1. GRN163L phase I and I/II clinical 
trials for various cancers. 
Outcomes:
 Good safety profiles and excellent 
pharmacokinetics and biodistribution properties.
 Maximum tolerated dose (MTD) = 9.4 mg/kg
 Toxicities: Increased coagulation time (aPTT), 
neutropenia and thrombocytopenia  at  doses 
higher than MTD.
GRN163L decreases cell growth and colony formation 
capacity through induction of apoptosis.
GRN163L potentiates the effects of various
radiotherapeutic and chemotherapeutic agents.
GRN163L inhibits tumor growth and reduces 
metastases in vivo.
Figure 8. Cell viability and number of HER2+ breast cancer
cells treated with GRN163L, mismatch control oligonucleotide
(MM), Trastuzumab, or the combination of GRN163L/MM with
Trastuzumab.
Figure 9. A) Colony formation assay of esophageal cancer cells pretreated with
GRN163L compared to sense control pretreated cells. B) Live/dead assay on
long term treated glioblastoma cancer stem cells compared to untreated
controls. Green cells: live cells, red cells: necrotic cells (apoptotic).
a) b)
4. GRN163L preclinical and clinical studies
4.1 Preclinical studies in vitro and in vivo.
A) Preclinical in vitro studies with human cancer cells                      
GRN163L inhibits telomerase activity GRN163L causes telomere shortening
B) Preclinical in vivo studies using mouse models
Treatment with GRN163L decreases tumorigenicity of 
cancer stem cells in vivo.
Figure 6. Telomerase activity of treated vs. untreated
pancreas cancer stem cells.
a) b)
Figure 7. Human myeloma cells treated with mismatch control oligonucleotide
(S7S) or GRN163L. A) Percentage of telomeres less than 1.4 kb (*p-value
<0.05). B) Number of detectable telomeres.
Figure 10. Tumor development in mice injected either with
treated or untreated pancreatic cancer stem cells. Postimplant =
secondary treatment with GRN163L in vivo.
Figure 11. Human breast cancer cells (treated vs. untreated)
were injected into mice. A) Primary tumor growth. B) Number and
size of lung metastasis.
a) b)
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Conclusion: Preclinical studies and clinical trials demonstrate that GRN163L is an
effective and promising drug for human cancer therapy. Anyway, the following issues
need to be furher investigated:
Inhibit telomerase activity
